Kathryn M Ziegler1, Robert V Considine2, Eben True1, Deborah A Swartz-Basile1, Henry A Pitt3, Nicholas J Zyromski4. 1. Department of Surgery, Indiana University School of Medicine, USA. 2. Division of Endocrinology, Department of Medicine, Indiana University School of Medicine, USA. 3. Department of Surgery, Temple University School of Medicine, USA. 4. Department of Surgery, Indiana University School of Medicine, USA. Electronic address: nzyromsk@iupui.edu.
Abstract
INTRODUCTION: Obesity accelerates the development and progression of pancreatic cancer, though the mechanisms underlying this association are unclear. Adipocytes are biologically active, producing factors such as hepatocyte growth factor (HGF) that may influence tumor progression. We therefore sought to test the hypothesis that adipocyte-secreted factors including HGF accelerate pancreatic cancer cell proliferation. MATERIAL AND METHODS: Murine pancreatic cancer cells (Pan02 and TGP-47) were grown in a) conditioned medium (CM) from murine F442A preadipocytes, b) HGF-knockdown preadipocyte CM, c) recombinant murine HGF at increasing doses, and d) CM plus HGF-receptor (c-met) inhibitor. Cell proliferation was measured using the MTT assay. ANOVA and t-test were applied; p < 0.05 considered significant. RESULTS: Wild-type preadipocyte CM accelerated Pan02 and TGP-47 cell proliferation relative to control (59 ± 12% and 34 ± 12%, p < 0.01, respectively). Knockdown of preadipocyte HGF resulted in attenuated proliferation vs. wild type CM in Pan02 cells (35 ± 5% vs. 68 ± 14% greater than control; p < 0.05), but proliferation in TGP-47 cells remained unchanged. Recombinant HGF dose-dependently increased Pan02, but not TGP-47, proliferation (p < 0.05). Inhibition of HGF receptor, c-met, resulted in attenuated proliferation versus control in Pan02 cells, but not TGP-47 cells. CONCLUSIONS: These experiments demonstrate that adipocyte-derived factors accelerate murine pancreatic cancer proliferation. In the case of Pan02 cells, HGF is responsible, in part, for this proliferation.
INTRODUCTION:Obesity accelerates the development and progression of pancreatic cancer, though the mechanisms underlying this association are unclear. Adipocytes are biologically active, producing factors such as hepatocyte growth factor (HGF) that may influence tumor progression. We therefore sought to test the hypothesis that adipocyte-secreted factors including HGF accelerate pancreatic cancer cell proliferation. MATERIAL AND METHODS:Murinepancreatic cancer cells (Pan02 and TGP-47) were grown in a) conditioned medium (CM) from murine F442A preadipocytes, b) HGF-knockdown preadipocyte CM, c) recombinant murineHGF at increasing doses, and d) CM plus HGF-receptor (c-met) inhibitor. Cell proliferation was measured using the MTT assay. ANOVA and t-test were applied; p < 0.05 considered significant. RESULTS: Wild-type preadipocyte CM accelerated Pan02 and TGP-47 cell proliferation relative to control (59 ± 12% and 34 ± 12%, p < 0.01, respectively). Knockdown of preadipocyte HGF resulted in attenuated proliferation vs. wild type CM in Pan02 cells (35 ± 5% vs. 68 ± 14% greater than control; p < 0.05), but proliferation in TGP-47 cells remained unchanged. Recombinant HGF dose-dependently increased Pan02, but not TGP-47, proliferation (p < 0.05). Inhibition of HGF receptor, c-met, resulted in attenuated proliferation versus control in Pan02 cells, but not TGP-47 cells. CONCLUSIONS: These experiments demonstrate that adipocyte-derived factors accelerate murinepancreatic cancer proliferation. In the case of Pan02 cells, HGF is responsible, in part, for this proliferation.
Authors: Lauren N Bell; Jennifer L Ward; Mikako Degawa-Yamauchi; Jason E Bovenkerk; RoseMarie Jones; Brenda M Cacucci; Christine E Gupta; Carol Sheridan; Kevin Sheridan; Sudha S Shankar; Helmut O Steinberg; Keith L March; Robert V Considine Journal: Am J Physiol Endocrinol Metab Date: 2006-06-06 Impact factor: 4.310
Authors: Michael G House; Yuman Fong; Dean J Arnaoutakis; Rohit Sharma; Corinne B Winston; Mladjan Protic; Mithat Gonen; Sara H Olson; Robert C Kurtz; Murray F Brennan; Peter J Allen Journal: J Gastrointest Surg Date: 2007-12-01 Impact factor: 3.452
Authors: Timothy K Williams; Ernest L Rosato; Eugene P Kennedy; Karen A Chojnacki; Jocelyn Andrel; Terry Hyslop; Cataldo Doria; Patricia K Sauter; Jordan Bloom; Charles J Yeo; Adam C Berger Journal: J Am Coll Surg Date: 2008-12-18 Impact factor: 6.113
Authors: Jalees Rehman; Dmitry Traktuev; Jingling Li; Stephanie Merfeld-Clauss; Constance J Temm-Grove; Jason E Bovenkerk; Carrie L Pell; Brian H Johnstone; Robert V Considine; Keith L March Journal: Circulation Date: 2004-03-01 Impact factor: 29.690
Authors: Abhishek Mathur; Henry A Pitt; Megan Marine; Romil Saxena; C Max Schmidt; Thomas J Howard; Attila Nakeeb; Nicholas J Zyromski; Keith D Lillemoe Journal: Ann Surg Date: 2007-12 Impact factor: 12.969
Authors: Matthew Benns; Charles Woodall; Charles Scoggins; Kelly McMasters; Robert Martin Journal: Ann Surg Oncol Date: 2009-06-26 Impact factor: 5.344
Authors: Ponnandai Somasundar; Krista A Frankenberry; Heath Skinner; Giridhar Vedula; David W McFadden; Dale Riggs; Barbara Jackson; Reyna Vangilder; Stanley M Hileman; Linda C Vona-Davis Journal: J Surg Res Date: 2004-05-01 Impact factor: 2.192
Authors: Patrick B White; Eben M True; Kathryn M Ziegler; Sue S Wang; Deborah A Swartz-Basile; Henry A Pitt; Nicholas J Zyromski Journal: J Gastrointest Surg Date: 2010-09-22 Impact factor: 3.452